Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β- d -Glucan Synthase: Implication for the Existing Susceptibility Breakpoint
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Thirteen Candida glabrata strains harboring a range of mutations in hot spot regions of FKS1 and FKS2 were studied. The mutations were linked to an echinocandin reduced susceptibility phenotype. Sequence alignments showed that 11 out of the 13 mutants harbored a mutation in FKS1 or FKS2 not previously implicated in echinocandin reduced susceptibility in C. glabrata . A detailed kinetic characterization demonstrated that amino acid substitutions in Fks1p and Fks2p reduced drug sensitivity in mutant 1,3-β- d -glucan synthase by 2 to 3 log orders relative to that in wild-type enzyme. These mutations were also found to reduce the catalytic efficiency of the enzyme ( V max ) and to influence the relative expression of FKS genes. In view of the association of FKS mutations and reduced susceptibility of 1,3-β- d -glucan synthase, an evaluation of the new CLSI echinocandin susceptibility breakpoint was conducted. Only 3 of 13 resistant fks mutants (23%) were considered anidulafungin or micafungin nonsusceptible (MIC > 2 μg/ml) by this criterion. In contrast, most fks mutants (92%) exceeded a MIC of >2 μg/ml with caspofungin. However, when MIC determinations were performed in the presence of 50% serum, all C. glabrata fks mutants showed MICs of ≥2 μg/ml for the three echinocandin drugs. As has been observed with Candida albicans , the kinetic inhibition parameter 50% inhibitory concentration may be a better predictor of FKS -mediated resistance. Finally, the close association between FKS1/FKS2 hot spot mutations provides a basis for understanding echinocandin resistance in C. glabrata .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“C. glabrata may upregulate FKS2 expression to compensate for its decreased catalytic capacity [36]”
From Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata (2012) · cites this paper as [36]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with azoles, resistance to echinocandin therapy frequently involves mutations in genes encoding the drug target, FKS1 (Candida, Cryptococcus, and Aspergillus spp.) and FKS2 (C. glabrata only)33,34.”
From Molecular mechanisms governing antifungal drug resistance (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“intrinsic genetic, structural, and binding variations in Fks enzymes across Candida species create distinct baseline susceptibilities and predispose certain species to develop heteroresistance under selective pressure from specific echinocandins [51].”
From Calcineurin‐Dependent Stress Adaptation Enables Caspofungin Heteroresistance Leading to Stable Resistance in Candida Glabrata (2026) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, FKS1 point mutations are commonly detected in ECN-resistant (ECN-R) Candida spp. (24, 25).”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Point mutations in one of two specific hot-spot regions of FKS genes increase the half maximal inhibition concentration (IC50) of an echinocandin in vitro by up to 3 orders of magnitude67.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [67]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics
White, T. J., Bruns, T., Lee, S., & Taylor, J. (1990) · PCR Protocols · doi:10.1016/b978-0-12-372180-8.50042-1 · Cited by 36,648
Self-citationA new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610 · cited 1×
“relative expression levels were evaluated using the Pfaffl method (23).”
MethodPCR protocols — A guide to methods and applications
(1990) · Trends in Genetics · doi:10.1016/0168-9525(90)90186-a · Cited by 11,781
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“glabrata infections are a concern due to their high mortality rates (38) and the tendency of this microorganism to rapidly develop resistance to azole antifungal agents (6, 11, 15, 25, 31, 34).”
BackgroundDenning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“The introduction of the antifungal drug caspofungin (CSF) in 2001 was a significant advance in the treatment of these infections since these lipopeptides’ mode of action is independent of existing antifungal drugs (7, 16, 36).”
BackgroundReference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,052
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953 · cited 1×
“glabrata infections are a concern due to their high mortality rates (38) and the tendency of this microorganism to rapidly develop resistance to azole antifungal agents (6, 11, 15, 25, 31, 34).”
BackgroundTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512 · cited 3×
“These IC50s were comparable with previous data obtained for other echinocandin-resistant Candida species strains with FKS mutations (13, 14, 21, 22).”
BackgroundResultSelf-citationPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Self-citation
Cited by
Items 201–300 of 335
Pfaller, M. A., Castanheira, M., Lockhart, S. R., & Jones, R. N. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0091-0 · Cited by 22
“Mutations in FKS proteins alter the GS enzyme kinetics resulting in significantly higher 50% inhibitory concentrations (IC50), as well as the kinetic inhibition constant (Ki), for the mutant enzymes when compared with corresponding enzymes from WT strains [61].”
Ceballos-Garzon, A., Monteoliva, L., Gil, C., Alvarez-Moreno, C., Vega-Vela, N. E., Engelthaler, D. M., Bowers, J., Le Pape, P., & Parra-Giraldo, C. M. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab454 · Cited by 18
Target Enzyme Mutations Confer Differential Echinocandin Susceptibilities in Candida kefyr
Staab, J. F., Neofytos, D., Rhee, P., Jiménez‐Ortigosa, C., Zhang, S. X., Perlin, D. S., & Marr, K. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00096-14 · Cited by 22
“glabrata Fks2p (F659 ) also confers RES in that species (27, 32).”
BackgroundMethodSelf-citationNiimi, K., Woods, M. A., Maki, K., Nakayama, H., Hatakenaka, K., Chibana, H., Ikeda, F., Ueno, K., Niimi, M., Cannon, R. D., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks112 · Cited by 18
Marcos-Zambrano, L. J., Escribano, P., Rueda, C., Zaragoza, Ó., Bouza, E., & Guinea, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01032-13 · Cited by 18
Genome-Wide Response to Drugs and Stress in the Pathogenic Yeast Candida glabrata
Pais, P., Galocha, M., & Teixeira, M. C. (2019) · Progress in molecular and subcellular biology · doi:10.1007/978-3-030-13035-0_7 · Cited by 18
Vale-Silva, L. A., Pinto, P., Lopes, V., Ramos, H., & Pinto, E. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1390-z · Cited by 17
“[10–14].”
Zhu, Y., Hager, K. M., Manjari, S. R., Banavali, N. K., Chaturvedi, V. P., & Chaturvedi, S. (2023) · Journal of Clinical Microbiology · doi:10.1128/jcm.01767-22 · Cited by 17
Ste11p MEKK signals through HOG, mating, calcineurin and PKC pathways to regulate the FKS2 gene
Wang, X., Sheff, M. A., Simpson, D. M., & Elion, E. A. (2011) · BMC Molecular Biology · doi:10.1186/1471-2199-12-51 · Cited by 17
“The Fks1p and Fks2p subunits of glucan synthase are major therapeutic targets of anti-fungal inhibitors and acquire resistance mutations during fungal infections in people [10,11].”
BackgroundCuenca‐Estrella, M. (2010) · PubMed · Cited by 40
Silver nanoparticles: an upcoming therapeutic agent for the resistant Candida infections
Perween, N., Khan, H. M., & Fatima, N. (2019) · Journal of Microbiology & Experimentation · doi:10.15406/jmen.2019.07.00240 · Cited by 18
Echinocandin Antifungal Drug Resistance in Candida Species: A Cause for Concern?
Sanguinetti, M., Posteraro, P., & Posteraro, B. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0131-2 · Cited by 17
Antifungal Resistance Testing and Implications for Management
Badali, H., & Wiederhold, N. P. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00354-6 · Cited by 17
Biomarkers of caspofungin resistance in Candida albicans isolates: A proteomic approach
Cesare, G. B. D., Hafez, A. I., Stead, D., Lloréns, C., & Munro, C. A. (2022) · Virulence · doi:10.1080/21505594.2022.2081291 · Cited by 19
“Reduced susceptibility to echinocandins has been attributed primarily to point mutations in the GSC1 (FKS1) gene that encodes the catalytic subunit of the glucan synthase complex, which can decrease sensitivity to the drug by several log orders [13,14].”
BackgroundSilva, L. N., Ramos, L. S., Oliveira, S. S. C., Magalhães, L. B., Cypriano, J. B. S., Abreu, F. D. Á., Macêdo, A. J., Branquinha, M. H., & dos Santos, A. L. S. (2023) · Journal of Fungi · doi:10.3390/jof9080859 · Cited by 16
Molecular Mechanisms of Resistance to Antifungals in Candida albicans
Ruiz‐Baca, E., Arredondo-Sánchez, R. I., Corral-Pérez, K., López-Rodríguez, A., Meneses‐Morales, I., Ayala‐García, V. M., & Martínez-Rocha, A. L. (2021) · Infectious diseases · doi:10.5772/intechopen.96346 · Cited by 23
Phenotypic Variability in a Coinfection With Three Independent Candida parapsilosis Lineages
Gómez-Molero, E., Willis, J. R., Dudakova, A., Carreté, L., Weig, M., Groß, U., Gácser, A., Gabaldón, T., & Bader, O. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01994 · Cited by 18
Fothergill, A. W., McCarthy, D. I., Bataineh, M. T. A., Sanders, C. J., McElmeel, M., & Wiederhold, N. P. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02659-15 · Cited by 16
Naskar, S., Prajapati, A., & Kaur, R. (2025) · FEMS Yeast Research · doi:10.1093/femsyr/foaf025 · Cited by 17
“T he contribution of C. glabrata mouse gut colo-nizers to caspofungin resistance was further highlighted by a recent study which sho w ed the emergence of mutations in CgFKS2 (codes for the caspofungin target enzyme) and CgFEN1 (codes for a fatty acid elongase, that is involved in sphingolipid biosynthesis) genes duri…”
InfluentialHassoun, Y., Aptekmann, A. A., Keniya, M. V., Gomez, R. Y., Alayo, N., Novi, G., Quinteros, C., Kaya, F., Zimmerman, M. D., Cáceres, D. H., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012521 · Cited by 16
Self-citationRecent insights into glucans biosynthesis and engineering strategies in edible fungi
Cui, F., Fu, X., Sun, L., Zan, X., Meng, L., & Sun, W.-J. (2023) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2023.2289341 · Cited by 15
“Product entrapped β-1,3-glucan synthase in C. glabrata showed a kinetic parameters V max and K m of 6.812 nmol/min and 0.133 mM [79].”
InfluentialMutational landscape and molecular bases of echinocandin resistance in Saccharomyces cerevisiae
Durand, R., Torbey, A. G., Giguère, M., Pageau, A., Dubé, A. K., Lagüe, P., & Landry, C. R. (2026) · Genetics · doi:10.1093/genetics/iyag055 · Cited by 16
“Despite a lower number of colonies for FKS1-HS2 (NNK and homolog pools), we managed to get sufficient coverage as we describe in the next section.”
Huang, C., Zhao, F., Lin, Y., Zheng, S., Liang, S., & Han, S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.04.113 · Cited by 19
The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus
Ostrosky-Zeichner, L. L., & Andes, D. R. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix239 · Cited by 14
Ben-Ami, R., Hilerowicz, Y., Novikov, A., & Giladi, M. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.02.008 · Cited by 12
“Improved classification of echinocandin susceptibility may potentially be achieved using modified testing methods, such as the addition of bovine serum albumin to culture medium (Garcia-Effron et al., 2009).”
BackgroundNickels, T. J., Gale, A. N., Harrington, A. A., Timp, W., & Cunningham, K. W. (2024) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkae173 · Cited by 12
The hidden threat: Unveiling the rise of antifungal drug resistance
Chaudhary, R., & Thakur, Z. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.108068 · Cited by 12
Accoceberry, I., Couzigou, C., Fitton‐Ouhabi, V., Biteau, N., & Noël, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky475 · Cited by 14
Espinel‐Ingroff, A., & Cantón, E. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70002-7 · Cited by 13
“metapsilosis (3) ≥ 1 (14-23) 32 (19) ≥ 1 (4-30) C.”
Bienvenu, A., Leboucher, G., & Picot, S. (2019) · Mycoses · doi:10.1111/myc.12929 · Cited by 12
Kuti, E. L., & Kuti, J. L. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.518143 · Cited by 14
“FKS gene mutations may have echinocandin MIC values in the susceptible range [40,41].”
BackgroundTóth, V., Nagy, C. T., Pócsi, I., & Emri, T. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4027-y · Cited by 11
“In some echinocandin-resistant C. glabrata isolates, mutations in FKS1 were accompanied with an elevated FKS1 expression as well suggesting that up-regulation of FKS1 expression can be an alternative mechanism to acquire echinocandin resistance (Garcia-Effron et al. 2009; Walker et al. 2010).”
BackgroundInhibition mechanism of the fungal β−1,3-glucan synthases by triterpenoid antifungal drugs
You, Z.-L., Sun, L., Wang, L.-X., Ni, Y.-R., Lyu, R., Chen, D., Yun, C.-H., Song, T., Song, Y., & Bai, L. (2026) · Nature Communications · doi:10.1038/s41467-026-69114-8 · Cited by 12
New antifungal agents for the treatment of candidaemia
Muñóz, P., Guinea, J., Rojas, L., & Bouza, E. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.007 · Cited by 15
Utility of Antifungal Susceptibility Testing and Clinical Correlations
Diekema, D. J., & Pfaller, M. A. (2011) · Humana Press eBooks · doi:10.1007/978-1-59745-134-5_8 · Cited by 11
Caspofungin therapy in immunocompromised children and neonates
Somer, A., Törün, S. H., & Salman, N. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.4 · Cited by 11
Mechanisms of Resistance to Antifungal Agents
White, T. C., & Hoot, S. J. (2011) · Wiley eBooks · doi:10.1128/9781555816728.ch127 · Cited by 10
Wright, W. F., Bejou, N., Shields, R. K., Marr, K. A., McCarty, T. P., & Pappas, P. G. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00512-19 · Cited by 8
“Echinocandins are fungicidal lipopeptides that inhibit synthesis of the major cell wall component -(1,3)-D-glucan by noncompetitive binding to the multimeric catalytic functional subunit of 1,3- -D-glucan synthase protein complex encoded by three putative related genes, FKS1, FKS2, and FKS3 (named for FK506 hypersensi…”
BackgroundEspinel‐Ingroff, A., Cantón, E., Peláez, T., & Pemán, J. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.12.010 · Cited by 9
Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?
Tapısız, A. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.7 · Cited by 8
Li, Y., Hou, X., Li, R., Liao, K., Ma, L., Wang, X., Ji, P., Kong, H., Xia, Y., Ding, H., et al. (2023) · BMC Microbiology · doi:10.1186/s12866-023-03105-3 · Cited by 7
“In C. glabrata , amino acid substitutions in both Fks1 and Fks2 occur, but are more common in Fks2 [15].”
BackgroundNatural product based approaches to overcome Candida glabrata and emerging AMR threats
Sahu, B. K., Patra, S. K., Sahu, M. C., & Panda, S. K. (2026) · Frontiers in Antibiotics · doi:10.3389/frabi.2026.1767032 · Cited by 7
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch130 · Cited by 9
Self-citationAmanloo, S., Shams‐Ghahfarokhi, M., Ghahri, M., & Razzaghi‐Abyaneh, M. (2018) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2018.01.002 · Cited by 7
Evaluation of Surveyor nuclease for rapid identification of FKS genes mutations in Candida glabrata
Khalifa, H. O., Arai, T., Majima, H., Watanabe, A., & Kamei, K. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.01.016 · Cited by 7
Rhodes, J. L. (2025) · Current topics in microbiology and immunology · doi:10.1007/82_2025_327 · Cited by 6
From patterns to prediction: machine learning and antifungal resistance biomarker discovery
Thorn, V., & Xu, J. (2025) · Canadian Journal of Microbiology · doi:10.1139/cjm-2024-0248 · Cited by 7
Clumping Morphology Influences Virulence Uncoupled from Echinocandin Resistance in Candida glabrata
Hu, C., Fong, G. R., Wurster, S., Kontoyiannis, D. P., & Beyda, N. D. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01837-21 · Cited by 6
Kumar, A., Francis, A., Hans, S., & Thakur, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_8 · Cited by 7
Tan, X., Baugh, K., Bulman, Z. P., & Wenzler, E. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00388-1 · Cited by 8
The Role of Resistance in Candida Infections: Epidemiology and Treatment
Sobel, J. D., & Akins, R. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_18 · Cited by 7
The Ins and Outs of Azole Antifungal Drug Resistance: Molecular Mechanisms of Transport
Zavřel, M., Esquivel, B. D., & White, T. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0667-3_29-1 · Cited by 7
Sharma, D., Paul, R. A., Chakrabarti, A., Bhattacharya, S., Soman, R. N., Shankarnarayan, S. A., Chavan, D., Singh, S., Das, P., Kaur, H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.09.196600 · Cited by 6
Diagnostics for human pathogenic fungal infections: Current status and future prospects
Huang, X., Moses, M., Nie, L., Wandera, E. A., & Chen, C. (2026) · hLife · doi:10.1016/j.hlife.2025.11.005 · Cited by 5
“Similarly, echinocandin resistance often arises from mutations in genes encoding the target enzyme, FKS1 (in Candida , Cryptococcus , and Aspergillus spp.) and FKS2 (in C. glabrata ) [147,148].”
Synergistic In Vitro Interaction of Isavuconazole and Isoquercitrin against Candida glabrata
Schwarz, P., Nikolskiy, I., Dannaoui, É., Sommer, F., Bange, G., & Schwarz, P. (2022) · Journal of Fungi · doi:10.3390/jof8050525 · Cited by 6
“Candida species can be acquired by mutations in the glucan synthase encoding genes, FKS1 and FKS2 [10,11].”
BackgroundInfluentialEmerging Resistance to Azoles and Echinocandins: Clinical Relevance and Laboratory Detection
Espinel‐Ingroff, A., Pfaller, M. A., Cantón, E., & Pemán, J. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0026-6 · Cited by 6
Tellería, O., Ezpeleta, G., Herrero, O., Miranda-Zapico, I., Quindós, G., & Cisterna, R. (2012) · Journal of Chromatography B · doi:10.1016/j.jchromb.2012.03.007 · Cited by 6
Gonzalez-Jimenez, I., Keniya, M. V., Aptekmann, A. A., Quinteros, C., Wilkerson, A., Arastehfar, A., Daneshnia, F., Perlin, D. S., & Shor, E. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00500-25 · Cited by 4
“The primers used by us, as well as primers used in previous studies that examined FKS2 expression (11, 13, 17–19), hybridized to FKS2 near the 5 ′ end of its open reading frame (ORF, Fig.”
InfluentialSelf-citationHomology modeling studies of beta(1,3)‐ D ‐glucan synthase of Moniliophthora perniciosa
Pinheiro, A. A. F., Taranto, A. G., Duarte, A. A., Goés‐Neto, A., Hora, B. T., Pereira, G. A. G., dos Santos, M. C., & de Assis, S. A. (2012) · International Journal of Quantum Chemistry · doi:10.1002/qua.24212 · Cited by 4
Multidrug- and Cross-Resistant Candida: the Looming Threat
Lackner, M., Martín‐Vicente, A., & Lass‐Flörl, C. (2014) · Current Fungal Infection Reports · doi:10.1007/s12281-014-0210-1 · Cited by 7
Pilmis, B., Yang, Z., Lanternier, F., & Lortholary, O. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00049-6 · Cited by 6
Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins
Pfaller, M. A., Diekema, D. J., Castanheira, M., & Jones, R. N. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0053-y · Cited by 4
“5 μg/mL may be more sensitive in detecting those strains with fks1/fks2 mutations [36, 37, 42].”
BackgroundAntifungal Resistance in Candida albicans
Seyedjavadi, S. S., Hatami, F., & Jahanshiri, Z. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004578 · Cited by 3
Mareș, M., Minea, B., Năstasă, V., Roșca, I., Bostănaru, A.-C., Marincu, I., Toma, V., Cristea, V. C., Murariu, C., & Pinteală, M. (2017) · Medical Mycology · doi:10.1093/mmy/myx059 · Cited by 3
Analysis of fks1 and fks2 gene mutations in invasive Candida glabrata strains from Pakistan
Memon, S., Ghanchi, N. K., Zafar, U., Farooqi, J. Q., Zaka, S., & Jabeen, K. (2022) · Mycoses · doi:10.1111/myc.13527 · Cited by 4
Zheng, L., Xu, Y., Wang, C., Yang, F. J., Dong, Y., & Guo, L. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01790-23 · Cited by 3
“The incidence of CSP resistance is rising in recent years (9–11).”
BackgroundMolecular Detection of Resistance to Echinocandins
Posteraro, B., Vella, A., Carolis, E. D., & Sanguinetti, M. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6515-1_23 · Cited by 3
Failure of Echinocandin Therapy in the Treatment of Candida glabrata Chorioretinitis
Mousselli, H. A., & Norwood, J. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31822fb437 · Cited by 3
Advances in Antifungal Susceptibility Testing of Candida, 2010–2012
Pfaller, M. A., Castanheira, M., & Jones, R. N. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0092-z · Cited by 3
Córdoba, S. B., Abiega, C. D., Agorio, I., Amigot, S., Ardizzoli, K., Giusiano, G., Guelfand, L. I., Moral, L. L., Maldonado, I., Pineda, G., et al. (2021) · Revista Argentina de Microbiología · doi:10.1016/j.ram.2021.02.002 · Cited by 3
Su, Y., Li, Y., Xiao, M., Guo, D., Perlin, D. S., Shor, E., Xu, Y., & Li, Y. (2026) · Advanced Science · doi:10.1002/advs.76369 · Cited by 2
Self-citationFungal Antimicrobial Resistance: Mechanisms, Drivers, and Global Clinical Burden
Baral, B. (2026) · ChemFoodChem · doi:10.1002/cfch.70026 · Cited by 2
The Role of Resistance in Candida Infections: Epidemiology and Treatment
Sobel, J. D., & Akins, R. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-595-8_18 · Cited by 4
Hosler, J. P., Hoang, N., & Edwards, K. S. (2023) · Mitochondrion · doi:10.1016/j.mito.2023.05.004 · Cited by 2
Tagirova, L. I., Farvazova, K. R., Valeeva, D. R., Orlova, M. D., Gubaidullin, I., Tulyabaeva, A. M., Abdulmanova, A. R., Tryapko, R. V., Shelyginsky, D. A., Khanafieva, A. R., et al. (2024) · Obstetrics Gynecology and Reproduction · doi:10.17749/2313-7347/ob.gyn.rep.2024.500 · Cited by 2
Microevolution of Antifungal Drug Resistance
Cowen, L. E. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0667-3_19-1 · Cited by 2
“echinocandins (Garcia-Effron et al. 2009).”
BackgroundA Case of Micafungin-Hyposensitive Candida glabrata Due to FKS2 Gene Mutation
Inui, S., Nakamura, T., Tanabe, K., Ohno, H., Koike, C., Okuda, K., Nakata, C., FUJIMOTO, H., Ohkura, H., Miyazaki, Y., et al. (2011) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.85.49 · Cited by 2
Baxa, J. A. V. D. (2014) · Clinical Microbiology Open Access · doi:10.4172/2327-5073.1000154 · Cited by 2
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683670438.mcm0134 · Cited by 2
Self-citationFactors Affecting Drug Resistance and Virulence in Fungal Pathogen
Sharma, P., Kumari, D., Kumari, P., Kumar, A., & Pasrija, R. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_7 · Cited by 2
Lee, Y.-H., Hsu, L.-H., Yu, Z.-H., Leong, K.-Q., Chiang, H.-S., & Chen, Y. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106595 · Cited by 2
Hsu, L.-H., Chou, Y. Y., Shen, T., Wieczorek, D., & Chen, Y. (2025) · Virulence · doi:10.1080/21505594.2025.2609407 · Cited by 1
Uncovering actionable trade-offs of antifungal resistance in a yeast pathogen
Nunez‐Rodriguez, J. C., Schikora-Tamarit, M. À., & Gabaldón, T. (2026) · Molecular Systems Biology · doi:10.1038/s44320-025-00185-3 · Cited by 1
Arastehfar, A. A., Daneshnia, F., Hovhannisyan, H., Cabrera, N., Jusuf, S., Salehi, M., Mansour, M. K., Gabaldón, T., Shor, E., & Perlin, D. S. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01801-25 · Cited by 1
“Since 1,3-β-D-glucan constitutes an integral component of the cell wall and FKS mutations are shown to decrease 1,3-β-D-glucan synthase catalytic activity (12) and its biosynthetic capacity, ECR mutants carry a fitness cost (13, 14).”
Self-citationChedraoui, C., Fattouh, N., Hachem, S. E., Sourenian, T., Bitar, L. E., Moheb, L. E., Sleiman, A., Bitar, I., Husni, R., & Khalaf, R. A. (2026) · Mycoses · doi:10.1111/myc.70181 · Cited by 1
Clinical Relevance of In Vitro Resistance of Echinocandins: a Focus on Candida parapsilosis
Kale-Pradhan, P. B., Wilhelm, S. M., & Johnson, L. B. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0087-9 · Cited by 1
“tropicalis isolates [21–23].”
Candida infections: Novel virulence factors and mechanisms of azole resistance
Nalina, K. (2014) · Malaysian Journal of Microbiology · doi:10.21161/mjm.58913 · Cited by 1
“loosely associated with the membrane named RHO1 (Garcia-Effron et al., 2009).”
InfluentialUse of Novel Tools to Probe Drug Resistance in Fungi
Zhao, Y., & Perlin, D. S. (2017) · Springer eBooks · doi:10.1007/978-1-4939-0694-9_21 · Cited by 1
Self-citationResistance in Candida albicans: Exploring the Cell Wall Barrier by Proteomics
Giuseppina, B. M., & Angiolella, L. (2015) · Chemotherapy Open access · doi:10.4172/2167-7700.1000165 · Cited by 1
Candidiasis and the impact of flow cytometry on antifungal drug discovery
Ku, T. S. N., Bernardo, S. M., Walraven, C. J., & Lee, S. A. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1377179 · Cited by 1
Self-citationDrug resistance in pathogenic species of Candida
Jaiswal, N., & Kumar, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91643-1.00014-4 · Cited by 3
Biswas, C., Marcelino, V. R., van Hal, S. J., Halliday, C. L., Martínez, E., Wang, Q., Kidd, S. E., Kennedy, K., Marriott, D. J. E., Morrissey, C. O., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02218 · Cited by 1
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683674849.mcm0134 · Cited by 1
Self-citationAccoceberry, I., Lefranc, M., Meunier, C., Quilès, F., Kordalewska, M., Biteau, N., Perlin, D. S., El‐Kirat‐Chatel, S., & Noël, T. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.08.647726 · Cited by 1
Self-citationSchiavone, M. (2014) · theses.fr (ABES) · doi:10.70675/8d8138d0zec90z4678zae5azea3e22f1f96c · Cited by 1
Mechanisms of Action of Antifungal Agents
Flowers, S. A., & Rogers, P. (2015) · CRC Press eBooks · doi:10.1201/b17871-14
Zein, H. A. (2014) · BEPA Boletim Epidemiológico Paulista
The Roles of Hsp90 and Calcineurin in Antifungal Drug Resistance
Singh, S. (2012) · TSpace (University of Toronto)
Shamsizadeh, A., Nikfar, R., Mombini, M., Keikhaei, B., Jafarian, H., & Badiee, P. (2018) · Archives of Pediatric Infectious Diseases · doi:10.5812/pedinfect.12399
Metadata
- Authors
- Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S.
- Affiliations
- Public Health Research Institute, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07103
- University of New Mexico (US)
- Rutgers New Jersey Medical School (US)
- University of Mississippi (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-09
- Volume
- 53
- Issue
- 9
- Pages
- 3690-3699
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2737881
- OpenAlex
- W2163061527
- Cited by
- 323
- References
- 40
- Citations by year
- 2026: 18 · 2025: 12 · 2024: 12 · 2023: 14 · 2022: 10 · 2021: 17 · 2020: 22 · 2019: 18 · 2018: 20 · 2017: 26 · 2016: 14 · 2015: 17 · 2014: 25 · 2013: 16 · 2012: 26
- FWCI
- 18.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (AI069397, R01AI069397)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida glabrata, echinocandin resistance, 1,3-β-D-glucan synthase, FKS1, FKS2, hot spot mutations, anidulafungin, micafungin, caspofungin, susceptibility breakpoints, enzyme kinetics, catalytic efficiency, antifungal resistance
- MeSH terms
- Antifungal Agents, Fungal Proteins, Glucosyltransferases, Reverse Transcriptase Polymerase Chain Reaction, Drug Resistance, Fungal, Candida glabrata, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.